Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

References

• Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2021;47:561–567. doi:10.1111/ced.14979
   PubMed Web of Science ®Google Scholar
• Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl2):ii18–ii25. doi:10.1136/ard.2004.033217
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–2820. doi:10.1080/09546634.2022.2081655
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: a Literature Review. Int J Mol Sci. 2020;21(5):1690. doi:10.3390/ijms21051690
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled Phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the Phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi:10.1016/j.jaad.2016.11.041
   PubMed Web of Science ®Google Scholar
• Gerdes S, Bräu B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854–1862. doi:10.1111/1346-8138.16128
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Camela E, Fabbrocini G, Marasca C. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020;33(2):e13238. doi:10.1111/dth.13238
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: a Review of the Real-World Evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. doi:10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e13964. doi:10.1111/dth.13964
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;33(5):2560–2564. doi:10.1080/09546634.2022.2036674
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1):e14673. doi:10.1111/dth.14673
   PubMed Web of Science ®Google Scholar
• Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2021;314:619–623. doi:10.1007/s00403-021-02200-7
   PubMed Web of Science ®Google Scholar
• Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Pérez-Gil A, Font-Ugalde P, Galán-Gutiérrez M. Risankizumab: efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines. Life. 2022;12(11):1883. doi:10.3390/life12111883
   PubMedGoogle Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022. doi:10.1080/14740338.2022.2160447
   Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Pavia G, et al. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: a 52-Week Retrospective Study. Dermatol Ther (Heidelb). 2022;12(10):2309–2324. doi:10.1007/s13555-022-00795-x
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524. doi:10.1111/dth.15524
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021;85(4):1028–1030. doi:10.1016/j.jaad.2021.01.025
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study. Dermatol Ther. 2022;35(1):e15214. doi:10.1111/dth.15214
   PubMed Web of Science ®Google Scholar
• Sinclair R, Thirthar Palanivelu V. Tildrakizumab for the treatment of psoriasis. Expert Rev Clin Immunol. 2019;15(1):5–12. doi:10.1080/1744666X.2019.1544493
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276–288. doi:10.1016/S0140-6736(17)31279-5
   PubMed Web of Science ®Google Scholar
• Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:548.
   Google Scholar
• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18:2297. doi:10.3390/ijms18112297
   PubMed Web of Science ®Google Scholar
• Tonini A, Gualtieri B, Panduri S, et al. A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents. Expert Opin Biol Ther. 2018;18(2):135–148. doi:10.1080/14712598.2018.1398729
   PubMed Web of Science ®Google Scholar
• Markham A. Tildrakizumab: first global approval. Drugs. 2018;78(8):845–849. doi:10.1007/s40265-018-0917-3
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Thaci D, Iversen L, et al. Tildrakizumab results in significant and sustained improvements in health-related quality of life in patients with moderate to severe psoriasis in a phase 3 trial (reSURFACE 1) [e-poster 8047]. AAD Annual Meeting. 2019;1:3265.
   Google Scholar
• European Medicines Agency. Assessment Report. Ilumetri. International Non-Proprietary Name: Tildrakizumab. 2018. Procedure no. EMEA/H/C/004514/0000.
   Google Scholar
• Thaçi D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: pooled Analyses from the reSURFACE Pivotal Studies. Dermatol Ther (Heidelb). 2022;12(10):2325–2341. doi:10.1007/s13555-022-00793-z
   PubMed Web of Science ®Google Scholar
• Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: results of a Real-World Prospective Cohort Study in Nonselected Patients. Dermatology. 2021;1–5.
   PubMed Web of Science ®Google Scholar
• Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: a single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228. doi:10.1111/dth.15228
   PubMed Web of Science ®Google Scholar
• Mastorino L, Cariti C, Susca S, et al. Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement. Dermatol Ther. 2022;35(11):e15818. doi:10.1111/dth.15818
   PubMed Web of Science ®Google Scholar
• Potestio L, Genco L, Villani A, et al. Reply to ‘Cutaneous adverse effects of the available COVID-19 vaccines in India: a questionnaire-based study’ by Bawane J et al. J Eur Acad Dermatol Venereol. 2022;36(11):e863–e864. doi:10.1111/jdv.18341
   PubMed Web of Science ®Google Scholar
• Becher G, Conner S, Ingram JA, et al. A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis. Dermatol Ther. 2022;12(10):2343–2354. doi:10.1007/s13555-022-00800-3
   Web of Science ®Google Scholar
• Zagaria O, Villani A, Ruggiero A, Potestio L, Fabbrocini G, Gallo L. New-onset lichen planus arising after COVID-19 vaccination. Dermatol Ther. 2022;35(5):e15374. doi:10.1111/dth.15374
   PubMed Web of Science ®Google Scholar
• Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37(1):85–92. doi:10.1111/jdv.18572
   PubMed Web of Science ®Google Scholar
• Marasca C, Ruggiero A, Napolitano M, Fabbrocini G, Megna M. May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? Med Hypotheses. 2020;143:109853. doi:10.1016/j.mehy.2020.109853
   PubMed Web of Science ®Google Scholar
• Brunasso A. Nail Psoriasis Improvement During Tildrakizumab Therapy: a Real-Life Experience. J Drugs Dermatol. 2022;21(8):914–916. doi:10.36849/JDD.6828
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: scalp, Nail, Palmoplantar and Genital Psoriasis. J Clin Med. 2022;11(9):2631. doi:10.3390/jcm11092631
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941.
   PubMed Web of Science ®Google Scholar
• Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103. doi:10.1111/jdv.18594
   PubMed Web of Science ®Google Scholar